Scarica l'app Stockscreener
4.145
10.09%
-0.465
Precedente Chiudi:
$4.61
Aprire:
$4.67
Volume 24 ore:
3.98M
Relative Volume:
2.40
Capitalizzazione di mercato:
$520.25M
Reddito:
$50.27M
Utile/perdita netta:
$-68.91M
Rapporto P/E:
-6.874
EPS:
-0.603
Flusso di cassa netto:
$-44.32M
1 W Prestazione:
-12.92%
1M Prestazione:
-13.83%
6M Prestazione:
-2.24%
1 anno Prestazione:
-43.53%
Intervallo 1D:
$3.99
$4.715
Intervallo di 1 settimana:
$4.57
$4.975
Portata 52W:
$2.93
$7.55
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Nome
Aquestive Therapeutics Inc
Settore
Telefono
908-941-1900
Indirizzo
30 TECHNOLOGY DRIVE, WARREN, NJ
Compare AQST vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
4.145 | 520.25M | 50.27M | -68.91M | -44.32M | -0.603 |
TAK
Takeda Pharmaceutical Co Adr
|
19.59 | 62.57B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.27 | 48.14B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.965 | 43.82B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
78.89 | 32.60B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
547.06 | 23.46B | 3.17B | 1.29B | 1.01B | 27.09 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-24 | Ripresa | Oppenheimer | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-04-22 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-03 | Iniziato | Lake Street | Buy |
| 2018-08-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-08-20 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027 - GlobeNewswire Inc.
Aquestive Therapeutics (NasdaqGM:AQST) Stock Forecast & Analyst Predictions - Simply Wall Street
Aquestive Therapeutics (AQST) CEO sells 25,000 shares in preset plan trade - Stock Titan
Aquestive Therapeutics CEO Barber sells $120,487 in shares By Investing.com - Investing.com UK
Aquestive Therapeutics CEO Barber sells $120,487 in shares - Investing.com
Aquestive (NASDAQ: AQST) CCO sells 8,750 shares after exercising options - Stock Titan
Cantor Fitzgerald reiterates Aquestive stock Overweight on Anaphylm profile By Investing.com - Investing.com Canada
Aquestive Therapeutics (AQST) insider adds 2,293 shares - Stock Titan
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com Canada
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com India
Aquestive at cantor healthcare conference: anaphylm launch nears By Investing.com - Investing.com UK
Aquestive Therapeutics (AQST) CEO boosts stake with warrant exercise - Stock Titan
AQST Stock Price, Quote & News - Syfe
Aquestive Therapeutics (AQST) COO adds shares via warrant exercise - Stock Titan
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Investors to Inquire about Securities Investigation - ACCESS Newswire
AQST SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Reach Out - accessnewswire.com
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - manilatimes.net
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aquestive Therapeutics, Inc. (AQST) And Encourages Stockholders to Connect - ACCESS Newswire
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - natlawreview.com
Blue Owl Capital Holdings LP Makes New $3.92 Million Investment in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics Earnings Call Highlights Anaphylm Progress - TipRanks
Latash Investments LLC Acquires New Holdings in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Aquestive Therapeutics: Potential Catalyst On The Horizon (NASDAQ:AQST) - Seeking Alpha
Aquestive (AQST) Q2 2026 Earnings Call Transcript - AOL.com
Aquestive Therapeutics CEO Daniel Barber Sells 25,000 Shares Under Rule 10b5-1 Plan - Kalkine Media
Aquestive (AQST) Closing Snapshot: Records a 0.70% Increase to $4.32 in the Current Update; Technical Focus - Vinanet
Aquestive Therapeutics CEO Daniel Barber disposes of 25,000 common shares worth $107,168 - Bitget
Aquestive (NASDAQ: AQST) CEO sells 25K shares under preset plan - Stock Titan
Aquestive Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Aquestive (NASDAQ: AQST) CCO's 2,714-share tax withholding detailed - Stock Titan
AQST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeut - The National Law Review
2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Encourages Aquestive Therapeutics, Inc. (AQST) Stockholders to Inquire about Securities Investigation | NDAQ:AQST | Press Release - Stockhouse
Walleye Capital LLC Purchases New Stake in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (NASDAQ:AQST) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aquestive Therapeutics, Inc. (AQST) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
LifeSci Capital Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Wasatch Advisors LP Has $5.76 Million Position in Aquestive Therapeutics, Inc. $AQST - MarketBeat
Aquestive Therapeutics (AQST) Stock Faces Cash Burn Questions As Anaphylm Nears Resubmission - Sahm
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ... - Yahoo! Finance Canada
Earnings call transcript: Aquestive Therapeutics tops revenue views in Q2 2026 - Investing.com Nigeria
Aquestive Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aquestive Therapeutics Inc Azioni (AQST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aquestive Therapeutics Inc Azioni (AQST) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Daniel Barber | Director |
Sep 15 '26 |
Proposed Sale |
4.88 |
50,000 |
244,000 |
0 |
| Korczynski Sherry | Chief Commercial Officer |
Sep 09 '26 |
Option Exercise |
2.65 |
8,750 |
23,188 |
244,439 |
| Korczynski Sherry | Chief Commercial Officer |
Sep 09 '26 |
Sale |
5.22 |
8,750 |
45,675 |
235,689 |
| Sherry M. Korczynski | Officer |
Sep 09 '26 |
Proposed Sale |
5.21 |
8,750 |
45,588 |
0 |
| Barber Daniel | President and CEO |
Aug 17 '26 |
Sale |
4.29 |
25,000 |
107,168 |
585,574 |
| Daniel Barber | Officer |
Aug 17 '26 |
Proposed Sale |
4.25 |
25,000 |
106,250 |
0 |
| Barber Daniel | President and CEO |
Jul 16 '26 |
Sale |
4.00 |
20,369 |
81,509 |
610,574 |
| Barber Daniel | President and CEO |
Jul 15 '26 |
Sale |
4.03 |
4,631 |
18,683 |
630,943 |
| Daniel Barber | Officer |
Jul 15 '26 |
Proposed Sale |
4.04 |
25,000 |
101,000 |
0 |
| Krop Julie | Director |
Jun 23 '26 |
Option Exercise |
0.71 |
25,000 |
17,830 |
25,000 |
5.61%
0.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):